Iratumumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD30 |
| Identifiers | |
| CAS Number | 640735-09-7  |
| ATC code | none |
| KEGG | D04612  |
| Chemical data | |
| Formula | C6358H9830N1682O1992S38 |
| Molecular mass | 170 kDa |
| (what is this?) (verify) |
|
Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.[1]
This drug was developed by Medarex, Inc.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Iratumumab, American Medical Association.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies for tumors
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
